Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed surgical stage III or IV endometrial cancer OR

- Any stage clear or serous papillary endometrial cancer

- Positive para-aortic lymph nodes allowed

- Tumor must be surgically reduced to 2 cm or less within 8 weeks of study

- Must have had hysterectomy and bilateral salpingo-oophorectomy

- No recurrent disease

- No metastases to lung or liver parenchyma or inguinal or scalene lymph nodes

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- GOG 0-2

Life expectancy:

- Not specified

Hematopoietic:

- Absolute neutrophil count greater than 2,000/mm^3

- Platelet count at least 100,000/mm^3

Hepatic:

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT no greater than 3 times ULN

Renal:

- Creatinine no greater than 1.5 times ULN

Other:

- No other prior or concurrent malignancy in the past 5 years except non-melanoma skin
cancer

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- No prior radiotherapy

Surgery:

- See Disease Characteristics

- No more than 8 weeks since prior surgery

Other:

- No prior anticancer therapy that would preclude study